Anti-PD-L1 antibodies and uses thereof
Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 116, a VH CDR3 of SEQ ID NO: 117, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.
1. An antibody or fragment thereof, wherein the antibody or fragment thereof has specificity to a human PD-L1 protein and comprises a heavy chain variable region (VH) comprising:
(a) a VH complementarity-determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 1;
(b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 116; and
(c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 117;
and a light chain variable region (VL) comprising:
(d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 4;
(e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 5; and
(f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
2. The antibody or fragment thereof of claim 1 , wherein the VH comprises the amino acid sequence of SEQ ID NO 149 and the VL comprises the amino acid sequence of SEQ ID NO: 150.
3. The antibody or fragment thereof of claim 1 , further comprising a heavy chain constant region, a light chain constant region, an Fc region, or the combination thereof.
4. The antibody or fragment thereof of claim 1 , wherein the antibody or fragment thereof is a chimeric antibody or a humanized antibody.
5. The antibody or fragment thereof of claim 4 , wherein the VH comprises one or more amino acid residues selected from the group consisting of:
(a) Ser at position 44,
(b) Ala at position 49,
(c) Ala at position 53,
(d) Ile at position 91,
(e) Glu at position 1,
(f) Val at position 37,
(g) Thr at position 40
(h) Val at position 53,
(i) Glu at position 54,
(j) Asn at position 77,
(k) Arg at position 94, and
(l) Thr at position 108, according to Kabat numbering.
6. The antibody or fragment thereof of claim 4 , wherein the VH comprises (a) Ser at position 44, (b) Ala at position 49, (c) Ala at position 53, and/or (d) Ile at position 91, according to Kabat numbering.
7. The antibody or fragment thereof of claim 4 , wherein the VL comprises one or more amino acid residues selected from the group consisting of:
(a) Ser at position 22,
(b) Gln at position 42,
(c) Ser at position 43,
(d) Asp at position 60, and
(e) Thr at position 63, according to Kabat numbering.
8. A bispecific antibody comprising a fragment of claim 1 and a second antigen-binding fragment having specificity to a molecular on an immune cell.
9. The bispecific antibody of claim 8 , wherein the molecule is selected from the group consisting of PD-1, CTLA-4, LAG-3, CD28, CD122, 4-1BB, TIM3, OX-40, OX40L, CD40, CD40L, LIGHT, ICOS, ICOSL, GITR, GITRL, TIGIT, CD27, VISTA, B7H3, B7H4, HEVM, BTLA, KIR, and CD47.
10. The bispecific antibody of claim 8 , wherein the fragment and the second fragment each is independently selected from a Fab fragment, a single-chain variable fragment (scFv), or a single-domain antibody.
11. The bispecific antibody of claim 8 , further comprising a Fc fragment.
12. A composition comprising the antibody or fragment thereof of claim 1 and a pharmaceutically acceptable carrier.
13. A polynucleotide nucleotide encoding one of the polypeptide chains of the antibody or fragment thereof of claim 1 .
14. An isolated cell comprising one or more polynucleotide encoding the antibody or fragment thereof of claim 1 .
15. A method of treating cancer expressing PD-L1 in a patient in need thereof, comprising administering to the patient an effective amount of the antibody or fragment thereof of claim 1 .
16. The method of claim 15 , wherein the cancer is a solid tumor.
17. The method of claim 15 , wherein the cancer is selected from the group consisting of bladder cancer, liver cancer, colon cancer, rectal cancer, endometrial cancer, leukemia, lymphoma, pancreatic cancer, small cell lung cancer, non-small cell lung cancer, breast cancer, urethral cancer, head and neck cancer, gastrointestinal cancer, stomach cancer, oesophageal cancer, ovarian cancer, renal cancer, melanoma, prostate cancer and thyroid cancer.
18. The method of claim 15 , further comprising administering to the patient a second cancer therapeutic agent.
19. A method of treating cancer expressing PD-L1 in a patient in need thereof, comprising:
(a) treating a T cell, in vitro, with the antibody or fragment thereof of claim 1 and
(b) administering the treated cell to the patient.